--- title: "Forte Biosciences (NASDAQ:FBRX) Releases Earnings Results, Misses Estimates By $0.09 EPS" type: "News" locale: "en" url: "https://longbridge.com/en/news/295707432.md" description: "Forte Biosciences (NASDAQ:FBRX) reported Q3 earnings of ($0.97) EPS, missing estimates by $0.09. Shares fell $0.09 to $76.78 on high volume. Multiple analysts downgraded the stock or set new targets, with Barclays and TD Cowen lowering ratings. Institutional ownership remains high at 77.63%, with recent activity from Bank of America and Citadel Advisors." datetime: "2026-08-12T20:41:26.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295707432.md) - [en](https://longbridge.com/en/news/295707432.md) - [zh-HK](https://longbridge.com/zh-HK/news/295707432.md) generator: "portal-rs" --- # Forte Biosciences (NASDAQ:FBRX) Releases Earnings Results, Misses Estimates By $0.09 EPS Forte Biosciences (NASDAQ:FBRX - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.97) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.09), FiscalAI reports. Get **Forte Biosciences** alerts: ## Forte Biosciences Price Performance Shares of Forte Biosciences stock traded down $0.09 during midday trading on Wednesday, hitting $76.78. 1,915,118 shares of the company were exchanged, compared to its average volume of 600,512. The firm has a market cap of $1.07 billion, a P/E ratio of -16.55 and a beta of 2.62. Forte Biosciences has a 52 week low of $9.91 and a 52 week high of $77.20. The firm has a 50 day simple moving average of $39.65 and a 200-day simple moving average of $31.86. ## Institutional Trading of Forte Biosciences A number of large investors have recently bought and sold shares of the stock. Global Retirement Partners LLC bought a new position in shares of Forte Biosciences during the fourth quarter valued at $27,000. Bank of America Corp DE boosted its position in Forte Biosciences by 5,641.8% in the third quarter. Bank of America Corp DE now owns 3,158 shares of the company's stock valued at $47,000 after buying an additional 3,103 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in Forte Biosciences in the third quarter valued at about $161,000. Jane Street Group LLC bought a new stake in Forte Biosciences during the fourth quarter worth about $228,000. Finally, Citadel Advisors LLC bought a new stake in Forte Biosciences during the third quarter worth about $234,000. 77.63% of the stock is currently owned by institutional investors. ## Analysts Set New Price Targets A number of research firms have weighed in on FBRX. Barclays downgraded shares of Forte Biosciences from an "overweight" rating to an "equal weight" rating and lifted their price target for the stock from $74.00 to $77.00 in a research note on Tuesday, July 28th. TD Cowen downgraded shares of Forte Biosciences from a "strong-buy" rating to a "hold" rating in a report on Monday, July 27th. Wall Street Zen downgraded shares of Forte Biosciences from a "sell" rating to a "strong sell" rating in a report on Saturday, July 25th. Weiss Ratings lowered shares of Forte Biosciences from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, July 28th. Finally, Evercore set a $77.00 target price on shares of Forte Biosciences in a research note on Monday, July 27th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $72.50. **Check Out Our Latest Stock Analysis on FBRX** ## About Forte Biosciences (Get Free Report) Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions. The company's lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis. ## Featured Articles - Five stocks we like better than Forte Biosciences - GE Vernova’s AI Power Boom Faces a Profit Test - Cardinal Health Earnings: Can Perfection Get Priced In Twice? - Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand - Legacy Jet Builders Stall While Embraer Accelerates to New Highs *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Forte Biosciences Right Now? Before you consider Forte Biosciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Forte Biosciences wasn't on the list. While Forte Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [FBRX.US](https://longbridge.com/en/quote/FBRX.US.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [BCS.US](https://longbridge.com/en/quote/BCS.US.md) - [TD.US](https://longbridge.com/en/quote/TD.US.md) - [EVR.US](https://longbridge.com/en/quote/EVR.US.md) - [GEV.US](https://longbridge.com/en/quote/GEV.US.md) - [CAH.US](https://longbridge.com/en/quote/CAH.US.md) - [NBIS.US](https://longbridge.com/en/quote/NBIS.US.md) - [EMBJ.US](https://longbridge.com/en/quote/EMBJ.US.md) - [34962G208.US](https://longbridge.com/en/quote/34962G208.US.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) - [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md) - [ERJ.US](https://longbridge.com/en/quote/ERJ.US.md) ## Related News & Research - [Forte Biosciences (NASDAQ:FBRX) Sees Strong Trading Volume - What's Next?](https://longbridge.com/en/news/296380566.md) - [Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX](https://longbridge.com/en/news/295559644.md) - [09:02 ETEvolved By Nature's Peptide Platform Used in FDA-Cleared Prescription Therapy for the Management of Atopic Dermatitis](https://longbridge.com/en/news/296496101.md) - [Turn Therapeutics says mouse study shows GX-03 cuts dermatitis severity 66%](https://longbridge.com/en/news/296487429.md) - [09:02 ETIMAGE Skincare Expands Its GLP-1-Targeted Skincare Innovation with New VOL.U.LIFT™ BODY Sculpt + Firm Treatment Complex](https://longbridge.com/en/news/296792631.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**